Chris Howerton
Stock Analyst at Jefferies
(2.65)
# 1,948
Out of 5,182 analysts
66
Total ratings
44.23%
Success rate
20.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Howerton
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNDA Vanda Pharmaceuticals | Maintains: Hold | $5 → $7.5 | $6.69 | +12.11% | 12 | Dec 31, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $79 → $125 | $47.02 | +165.84% | 3 | Dec 11, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $11 → $8 | $5.96 | +34.23% | 5 | Jan 2, 2025 | |
| MIST Milestone Pharmaceuticals | Downgrades: Hold | $8 → $4 | $1.87 | +113.90% | 4 | Jun 20, 2023 | |
| VERU Veru Inc. | Upgrades: Hold | $10 | $2.29 | +336.68% | 3 | Jun 7, 2023 | |
| BTAI BioXcel Therapeutics | Downgrades: Hold | $320 → $352 | $1.10 | +31,900.00% | 2 | Mar 10, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Underperform | $720 | $14.75 | +4,781.36% | 2 | Feb 8, 2023 | |
| CGEN Compugen | Downgrades: Underperform | $0.5 | $2.92 | -82.88% | 2 | Feb 8, 2023 | |
| URGN UroGen Pharma | Downgrades: Hold | $35 → $10 | $24.31 | -58.86% | 1 | Feb 8, 2023 | |
| APLS Apellis Pharmaceuticals | Downgrades: Hold | $70 → $40 | $40.94 | -2.30% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $57 → $61 | $32.08 | +90.15% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $90 | $182.72 | -50.74% | 3 | Sep 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $33.55 | +96.72% | 9 | Sep 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $7.04 | +212.50% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $1.20 | +1,650.00% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $0.86 | +2,457.84% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $21 | $22.11 | -5.02% | 6 | Apr 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $80 → $580 | $8.09 | +7,069.34% | 2 | Aug 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $63 → $60 | $2.18 | +2,652.29% | 1 | Aug 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 | $45.08 | -64.51% | 2 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $102.62 | -73.69% | 1 | Jul 15, 2020 |
Vanda Pharmaceuticals
Dec 31, 2025
Maintains: Hold
Price Target: $5 → $7.5
Current: $6.69
Upside: +12.11%
Structure Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $79 → $125
Current: $47.02
Upside: +165.84%
Ardelyx
Jan 2, 2025
Maintains: Buy
Price Target: $11 → $8
Current: $5.96
Upside: +34.23%
Milestone Pharmaceuticals
Jun 20, 2023
Downgrades: Hold
Price Target: $8 → $4
Current: $1.87
Upside: +113.90%
Veru Inc.
Jun 7, 2023
Upgrades: Hold
Price Target: $10
Current: $2.29
Upside: +336.68%
BioXcel Therapeutics
Mar 10, 2023
Downgrades: Hold
Price Target: $320 → $352
Current: $1.10
Upside: +31,900.00%
Avalo Therapeutics
Feb 8, 2023
Downgrades: Underperform
Price Target: $720
Current: $14.75
Upside: +4,781.36%
Compugen
Feb 8, 2023
Downgrades: Underperform
Price Target: $0.5
Current: $2.92
Upside: -82.88%
UroGen Pharma
Feb 8, 2023
Downgrades: Hold
Price Target: $35 → $10
Current: $24.31
Upside: -58.86%
Apellis Pharmaceuticals
Nov 10, 2022
Downgrades: Hold
Price Target: $70 → $40
Current: $40.94
Upside: -2.30%
Oct 14, 2022
Upgrades: Buy
Price Target: $57 → $61
Current: $32.08
Upside: +90.15%
Sep 30, 2022
Maintains: Buy
Price Target: $92 → $90
Current: $182.72
Upside: -50.74%
Sep 17, 2021
Initiates: Buy
Price Target: $66
Current: $33.55
Upside: +96.72%
Aug 23, 2021
Initiates: Buy
Price Target: $22
Current: $7.04
Upside: +212.50%
Aug 10, 2021
Initiates: Buy
Price Target: $21
Current: $1.20
Upside: +1,650.00%
May 25, 2021
Initiates: Buy
Price Target: $22
Current: $0.86
Upside: +2,457.84%
Apr 6, 2021
Downgrades: Hold
Price Target: $40 → $21
Current: $22.11
Upside: -5.02%
Aug 11, 2020
Upgrades: Buy
Price Target: $80 → $580
Current: $8.09
Upside: +7,069.34%
Aug 7, 2020
Downgrades: Underperform
Price Target: $63 → $60
Current: $2.18
Upside: +2,652.29%
Aug 5, 2020
Downgrades: Hold
Price Target: $16
Current: $45.08
Upside: -64.51%
Jul 15, 2020
Initiates: Buy
Price Target: $27
Current: $102.62
Upside: -73.69%